Unlike the post hoc analysis of the IMpower150 study, this study showed that the concurrent STK11/LKB1 mutation in KRAS mutant NSCLC was associated with an inferior ORR to PD-1 blockade when compared with KRAS mutation without STK11/LKB1 mutation and KRAS mutation with P53 mutations groups (7.4, 28.6 and 35.7% (P <0.001)). This evidence concerns the gene KRAS and non-small cell lung carcinoma.